Paraaortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18-Fluorodeoxyglucose PET (Positron Emission Tomography) in Advanced Cervical Cancer: Final Results of a Prospective Observational Cohort Study

被引:0
|
作者
Sasidharan, Ajay [1 ]
Mahantshetty, Umesh [1 ,2 ]
Chopra, Supriya [3 ]
Gurram, Lavanya [3 ]
Purandare, Nilendu [4 ]
Rangarajan, Venkatesh [4 ]
Shrivastava, Shyam Kishore [5 ]
机构
[1] Amrita Inst Med Sci, Dept Radiat Oncol, Kochi, India
[2] Homi Bhabha Canc Hosp & Res Ctr, Dept Radiat Oncol, Unit Tata Mem Ctr, Vishakapatnam, India
[3] Homi Bhabha Natl Inst, Tata Mem Hosp, Dept Radiat Oncol, Mumbai, Maharashtra, India
[4] Homi Bhabha Natl Inst, Tata Mem Hosp, Dept Nucl Med, Mumbai, Maharashtra, India
[5] Apollo Hosp, Dept Radiat Oncol, Navi Mumbai, India
关键词
PET; Cervical cancer; Para-aortic; EXTENDED-FIELD IRRADIATION; F-18-FDG PET; FDG-PET; CARCINOMA; BRACHYTHERAPY; METASTASIS; RADIATION; NODES; CHEMOTHERAPY; METAANALYSIS;
D O I
10.1007/s40944-021-00565-1
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose The purpose of this study was to evaluate the use of 18-fluorodeoxyglucose positron emission tomography (PET) in detecting paraaortic nodes and for response assessment/follow-up in advanced cervical cancer. Methods From 2005 to 2008, 96 patients with stage IIB & IIIB cervical cancer were included in the study. PET/CT (PET/computed tomography) was done at baseline and post-treatment at 6, 12, 18 and 24 months of follow-up. Extended-field radiotherapy was given to the patients with positive paraaortic node in CT scan. Results Nineteen patients (19.8%) received extended-field radiotherapy in view of positive paraaortic node in CT scan. Six patients (6.25%) had CT-negative PET-positive paraaortic node and two patients had CT positive PET-negative paraaortic node. Median follow-up was 80 months (interquartile range 56-106 months). The 5 year disease-free survival of patients with CT & PET-negative paraaortic node, CT-negative PET-positive paraaortic node and CT positive paraaortic node were 71%, 60% and 33%, respectively (p = 0.002). The 5-year overall survival of patients with complete metabolic response (n = 66), partial metabolic response (n = 9) and progressive metabolic disease (n = 21) was 84.8%, 26.7% and 17.1%, respectively (p < 0.001). Among the patients with relapse detected in PET/CT (n = 28), 18 had PET done at scheduled follow-up, but with no significant difference in post-relapse survival (median: 10.5 vs 7 months; p = 0.164). Out of 14 relapses detected at 6-month PET/CT, 11 included nodal/systemic relapse. Fifty percent of patients with >= 2cm node had persistent nodal disease at 6 months PET-CT. Conclusion PET-CT at baseline resulted in a small incremental benefit in detecting avid paraaortic nodes. Patients with routine follow up PET detected relapse but did not have significantly improved post relapse survivals. Further prospective studies with PET-CT response assessment in node positive patients and its impact on salvage treatment is warranted.
引用
收藏
页数:9
相关论文
共 37 条
  • [31] Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study
    Kelly-Morland, Christian
    Rudman, Sarah
    Nathan, Paul
    Mallett, Susan
    Montana, Giovanni
    Cook, Gary
    Goh, Vicky
    BMC CANCER, 2017, 17
  • [32] Clinical utility of 18F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study
    Rodado-Marina, Sonia
    Coronado-Poggio, Monica
    Maria Garcia-Vicente, Ana
    Ramon Garcia-Garzon, Jose
    Carlos Alonso-Farto, Juan
    Crespo de la Jara, Aurora
    Maldonado-Suarez, Antonio
    Rodriguez-Fernandez, Antonio
    BJU INTERNATIONAL, 2015, 115 (06) : 874 - 883
  • [33] Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study
    Gorin, Michael A.
    Rowe, Steven P.
    Patel, Hiten D.
    Vidal, Igor
    Mana-ay, Margarita
    Javadi, Mehrbod S.
    Solnes, Lilja B.
    Ross, Ashley E.
    Schaeffer, Edward M.
    Bivalacqua, Trinity J.
    Partin, Alan W.
    Pienta, Kenneth J.
    Szabo, Zsolt
    De Marzo, Angelo M.
    Pomper, Martin G.
    Allaf, Mohamad E.
    JOURNAL OF UROLOGY, 2018, 199 (01) : 126 - 132
  • [34] Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer final - results from the prospective German TLK cohort study
    von Verschuer, Ulla
    Schnell, Roland
    Tessen, Hans Werner
    Eggert, Jochen
    Binninger, Adrian
    Spring, Lisa
    Jaenicke, Martina
    Marschner, Norbert
    LUNG CANCER, 2017, 112 : 216 - 224
  • [35] DaPeCa-3: promising results of sentinel node biopsy combined with 18F-fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node-negative patients with penile cancer - a national study from Denmark
    Jakobsen, Jakob K.
    Alslev, Louise
    Ipsen, Pia
    Costa, Junia C.
    Krarup, Kim P.
    Sommer, Peter
    Nerstrom, Henrik
    Toft, Birgitte G.
    Hoyer, Soren
    Bouchelouche, Kirsten
    Jensen, Jorgen B.
    BJU INTERNATIONAL, 2016, 118 (01) : 102 - 111
  • [36] Sequential Imaging Characteristics and Potential Role of F18 Fluorodeoxyglucose Positron Emission Tomography/CT in the Evaluation of Treatment Response in Cases of Spinal Tuberculosis Without Neurological Involvement: Results From a Pilot Study
    Rai, Ankit
    Dahuja, Anshul
    Choudhary, Ranjeet
    Sharma, Amit
    Sankhla, Shantilal
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [37] Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang, Jin-Ji
    Wang, Shu-Xia
    Zhong, Wen-Zhao
    Xu, Chong-Rui
    Yan, Hong-Hong
    Wu, Yi-Long
    NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (12) : 1113 - 1120